CoImmune, Inc.
PrivateLast Round
Series A
Nov 10, 2020
Total Funding Raised
$56.1M
Company Overview
CoImmune, Inc. operates in Healthcare & Life Sciences and is based in Durham, North Carolina. Its latest recorded funding round was a Series A round in November 2020.
CoImmune, Inc. is a biotechnology company that specializes in the development of immuno-oncology therapies based on its two proprietary platform technologies, an autologous RNA-loaded dendritic cell technology and an allogeneic CAR-CIK technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CoImmune, Inc. Comparables
Compare CoImmune, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Diakonos Oncology | 82% | |
| CellxLife | 80% | |
| AiVita Biomedical | 74% |
For institutional investors. Book with your work email.
CoImmune, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 10, 2020 | ||||
| Corporate Funding | Feb 13, 2019 |
For institutional investors. Book with your work email.
CoImmune, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DSC Investment | Series A |
| Korea Investment Partners | Series A |
| SCM Lifescience | Corporate Funding, Series A |
| Brain Asset Management Co.,Ltd. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2020
$45M round with SCM Lifescience and Genexine Inc.
- Feb 13, 2019
$11.1M raised from SCM Lifescience and Genexine Inc.
For institutional investors. Book with your work email.
CoImmune, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CoImmune, Inc.'s valuation, stock price, and market status.
Is CoImmune, Inc. a public or private company?
CoImmune, Inc. is a private company.
What is the current stock price of CoImmune, Inc.?
CoImmune, Inc. is a private company, so its shares have no public market price. Caplight tracks CoImmune, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CoImmune, Inc. worth (valuation)?
Valuation information for CoImmune, Inc. is not publicly available.
Can I buy CoImmune, Inc. stock?
CoImmune, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CoImmune, Inc.'s last funding round?
CoImmune, Inc.'s most recent funding round was Series A on November 10, 2020.
Who are the main investors in CoImmune, Inc.?
Key investors in CoImmune, Inc. include DSC Investment, Korea Investment Partners, SCM Lifescience, Brain Asset Management Co.,Ltd..
Will CoImmune, Inc. IPO soon?
No public IPO plans have been announced for CoImmune, Inc..
How can I track CoImmune, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in CoImmune, Inc.'s shares on secondary markets.